Holen Sie sich die Stockscreener-App
185.39
0.77%
-1.43
Handel nachbörslich:
185.39
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$186.82
Offen:
$186.71
24-Stunden-Volumen:
657.71K
Relative Volume:
0.70
Marktkapitalisierung:
$20.73B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
24.92
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
+1.12%
1M Leistung:
+3.77%
6M Leistung:
+11.91%
1J Leistung:
+21.58%
1-Tages-Spanne:
$183.62
$187.26
1-Wochen-Bereich:
$182.90
$187.96
52-Wochen-Spanne:
$146.17
$187.96
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
185.39 | 20.89B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
459.22 | 176.72B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
181.46 | 133.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
618.17 | 50.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.89 | 35.26B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
176.69 | 30.81B | 15.70B | 1.24B | 2.01B | 6.91 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics (NYSE:DGX) SVP Sells $5,293,250.56 in Stock - MarketBeat
Is Quest Diagnostics Stock Underperforming the Dow? - MSN
Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025 - Nasdaq
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant - Yahoo Finance
Quest Diagnostics and Guardant Health collaborate for blood-based cancer screening - ROI-NJ
Leading Diagnostics Provider Quest to Release Q3 2025 Results Before Market Open October 21 - Stock Titan
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States - BioSpace
Quest Diagnostics Incorporated $DGX Shares Purchased by Toth Financial Advisory Corp - MarketBeat
Wedge Capital Management L L P NC Sells 18,080 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE:DGX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - sharewise.com
Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration - TradingView
Largest-Ever Lab Integration: Quest Diagnostics Teams with Epic to Transform 2,000 Testing Centers Nationwide - Stock Titan
Stock Traders Purchase High Volume of Quest Diagnostics Put Options (NYSE:DGX) - MarketBeat
Contravisory Investment Management Inc. Acquires Shares of 3,078 Quest Diagnostics Incorporated $DGX - MarketBeat
Czech National Bank Buys 1,792 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer - The Malaysian Reserve
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? - Yahoo Finance
Quest Diagnostics (DGX) Partners with Rutgers for Lung Cancer Re - GuruFocus
Breakthrough Cancer Detection: Quest's Haystack and Rutgers Test DNA-Guided Lung Cancer Treatment - Stock Titan
IFM Investors Pty Ltd Purchases 1,676 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
15,753 Shares in Quest Diagnostics Incorporated $DGX Acquired by Strs Ohio - MarketBeat
Jobs Data: What are Quest Diagnostics Incorporated’s earnings expectations2025 Technical Patterns & Accurate Buy Signal Alerts - خودرو بانک
Zevenbergen Capital Investments LLC Invests $728,000 in Quest Diagnostics Incorporated $DGX - MarketBeat
First Hawaiian Bank Acquires New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Martin Capital Partners LLC Has $917,000 Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
AG2R LA Mondiale Gestion D Actifs Buys Shares of 6,361 Quest Diagnostics Incorporated $DGX - MarketBeat
Parallel Advisors LLC Buys 100 Shares of Quest Diagnostics Incorporated $DGX - Defense World
Is Quest Diagnostics Incorporated a strong candidate for buy and holdRate Cut & Step-by-Step Swing Trade Plans - khodrobank.com
Voya Investment Management LLC Raises Holdings in Quest Diagnostics Incorporated $DGX - Defense World
Pensionfund Sabic Has $1.30 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
NewEdge Advisors LLC Grows Position in Quest Diagnostics Incorporated $DGX - MarketBeat
WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App - Yahoo Finance
Focus Partners Wealth Grows Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (DGX): A Bull Case Theory - MSN
Quest Diagnostics Incorporated $DGX Shares Bought by Geneos Wealth Management Inc. - Defense World
Quest Diagnostics Incorporated $DGX Holdings Decreased by Intech Investment Management LLC - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Bought by Integrity Alliance LLC. - MarketBeat
AQR Capital Management LLC Sells 91,935 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Advisors Capital Management LLC Acquires 6,771 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Goldman Sachs Group Inc. Has $126.23 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Fundamentals Check: What makes Quest Diagnostics Incorporated stock attractive today2025 Earnings Impact & High Return Trade Guides - خودرو بانک
Ransom Advisory Ltd Purchases Shares of 1,700 Quest Diagnostics Incorporated $DGX - MarketBeat
Fred Alger Management LLC Increases Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):